Kiniksa Pharmaceuticals International, plc KNSA
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Kiniksa Pharmaceuticals International, plc is a global biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapies for patients with serious unmet medical needs, particularly in cardiovascular and inflammatory diseases. Its lead product, ARCALYST (rilonacept), is an interleukin-1…
SectorHealthcare
ExchangeNASDAQ
IndustryDrug Manufacturers - Specialty & Generic
CountryUnited Kingdom
Employees366
TickerKNSA
Statistics
Market Cap$4.12B
Revenue (TTM)$677.6M
Net Income$59.0M
Net Margin8.7%
EPS$0.75
P/E57.02
P/S5.29
P/B6.31
EV/EBITDA37.23
ROE13.7%
Dividend Yield—
Price$53.75
Data: Twelve Data · Revenue = mcap / P/S